ARCTIC Study

Final results of Australasian Gastro-Intestinal Trials Group (AGITG) ARCTIC Study - An international audit of raltitrexed for patients with cardiac toxicity (CT) induced by Fluoropyrimidines (FP)

Timothy Price, Kate Wilson, John Simes, Desmond Yip, Niall Tebbutt, Chris Karapetis, Val Gebski, Marion Fournier, David Ferry, David Ransom

AGITG & OCTO (Oncology Clinical Trials Office - Oxford)
Disclosures

- Timothy Price has participated in research and has been an uncompensated member of advisory boards for:
  - AMGEN
  - MERCK
  - BAYER
  - NOVARTIS
  - ROCHE
  - IPSEN
Background

- Cardiac toxicity of FP is a potentially lethal toxicity
- Incidence ranges from 1.2% to 18%
- Capecitabine also causes cardiotoxicity in 3-6.2%
- Bolus 5FU has the lowest rate (2.2-2.4%)
- Asymptomatic ECG changes may occur in up to 88% of patients
- Coronary vasospasm is the most common form, although direct myocardial toxicity is also reported
- Risk factors are: higher doses of FP; prior chest radiation; history of cardiovascular disease; prior cardiotoxic agents.

Background (2)

- The majority of cardiac events occur in the first cycle
- Cardiotoxicity is generally reversible after cessation of 5FU therapy
- Re-exposure risk is reported to be 20-100%
- Nitrates and calcium blockers are sometimes used in an attempt to prevent cardiotoxicity

Becker et al; Drugs 1999 (57) 475, Jenson; Cancer Chemother Pharmacol 2006 (4) 487,
Raltitrexed

- a direct and specific thymidylate synthase inhibitor with similar activity to 5FU in colorectal cancer in Phase III trials (3 of 4)
- no obvious reported cardiotoxicity in initial Phase II/III trails.
- has been reported as an alternate option for patients with 5FU induced cardiotoxicity in a number of case reports

ARCTIC Aim

- Primary Aim: To determine if for patients who experienced cardiac toxicity from 5FU or capecitabine, the substitution with raltitrexed resulted in no further cardiac toxicity.

- Target population: Male and female patients aged ≥ 18 years old who have experienced cardiac toxicity from 5FU or capecitabine and who were given raltitrexed following the cardiac event.
Methods

- Raltitrexed treatment: Between January 2004 to December 2011
- Retrospective case note review of all patients who had cardiotoxicity from FP, and were subsequently switched to raltitrexed
- Baseline cardiac risk factors were documented
  - Dyslipidaemia, hypertension, past smoker, present smoker, diabetes and past history of IHD
Methods (2)

- Rates of cardiac events pre and post raltitrexed treatment were assessed

- Cardiotoxicity was defined as:
  - Angina/typical ischaemic chest pain
  - Myocardial infarct (MI)
  - Atypical pain with ECG/troponin changes
  - Arrhythmia

- A coronary angiogram was not mandatory
Statistical considerations

- Current evidence suggests the rate of cardiac events due to continuing FP after cardiac events is at least 20%
- In 40 patients treated with raltitrexed:
  - If at least 13 events were observed it would suggest the event rate is higher than that of continuing FP
  - If <4 events were observed in 40 patients treated with raltitrexed it would suggest cardiotoxicity is lower in comparison to continuing these patients on FP
- These rates were based on a 95% confidence interval for a true rate of cardiac toxicity of 20%
Results

- 12 institutions in Australia and the UK provided data
- 42 patients were treated with raltitrexed following a cardiac event while on FP during the study period
- Median age 62 years (range 36-81)
- 64% were male
- Prior ischaemic heart disease: 9 of 34 (26%)
- Cardiac risk factors:
  - Nil 5 (12%)
  - One 14 (33%)
  - Two 12 (29%)
  - Three 11 (26%)
Results - demographics

- Cancer Diagnosis
  - Colorectal 93%, Oesophageal 5%, Biliary 2%

- Chemotherapy
  - Fluoropyrimidine (FP) alone 11 (26%)
  - Epirubicin/Cispaltin/FP 1 (2%)
  - Platinum/FP 26 (62%)
  - Irinotecan/FP 4 (10%)

- Fluoropyrimidine
  - FP bolus 7 (17%)
  - FP infusion 26 (62%)
  - Capecitabine 9 (21%)
FP - first cardiac event

- Time to event: median 1 cycle (range 1-11)
- 61% in first cycle
- 83% within two cycles
- 48% (20 patients) typical pain, normal cardiac enzymes and ECG
- 19% (8 patients) typical pain and ECG changes but normal cardiac enzymes
- 29% (12 patients) had a myocardial infarction
Following their first event, nine patients were re-challenged with 5FU and had a further cardiac event (angina)
- 1 calcium antagonist, and 1 nitrate added
- 1 reduced dose 5FU
- 1 patients was switched to bolus 5FU

All patients (100%) had recurrent typical cardiac chest pain, two patients associated with ECG changes

Two patients had a third cardiac event prior to switching to raltitrexed
Raltitrexed

- Median number of cycles 6 (range 1-21)
- Relevant concomitant medications
  - Aspirin 8pts, calcium antagonist 6pts, nitrate 8pts
- Raltitrexed regimen used
  - Single agent 24%
  - Combination 76%
- No patients had further definitive cardiac events on raltitrexed
- Comparing the rate of cardiac events due to continuing FP after cardiac events (~20%) to no cardiac events on raltitrexed:
  - 0 events (95% CI 0-8.4), $P = .001$
Possible cardiac event on raltitrexed

- 69 y.o. Male with metastatic colorectal cancer
- Two prior cardiac events (typical chest pain)
  - Cycle 1 on day 3, and cycle 3 on day 1 (6hr post infusion)
- Prior therapy infusion 5FU/oxaliplatin x 3 cycles
- Current event
  - Day 14 after cycle 12 of raltitrexed
  - Undergoing rectal RT
  - Presented acute abdomen, diagnosis of perforation/peritonitis and SVT and anterior ischaemia clinically/ECG, treated IV/oral metoprolol
  - Patient died 24-48 hours later due to complications of peritonitis.
  - Likely arrhythmia secondary to infection/peritonitis
Conclusions

- This is the largest reported series of patients where raltitrexed substitution has occurred for FP cardiotoxicity.
- The majority of FP toxicity reported here would be consistent with reversible coronary spasm.
- The majority of events occurred in the first cycle (61%), and 83% within second cycle.
- 88% of patients had at least one cardiac risk factor.
- 26% of patients had a history of definite IHD.
- There was no cases of definite cardiac toxicity attributable to raltitrexed.
- Ralitrexed is a safe alternative option when FP cardiotoxicity is diagnosed.